NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$38.22
$38.22
50-Day Range
$37.81
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DRNA stock logo

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

DRNA Stock News Headlines

DRNA Jul 2022 40.000 call(CONTR
DRNA Jan 2022 22.500 call
Dicerna Pharmaceuticals: Q3 Earnings Snapshot
See More Headlines
Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRNA
Employees
302
Year Founded
N/A

Profitability

Net Income
$-112,750,000.00
Pretax Margin
-63.82%

Debt

Sales & Book Value

Annual Sales
$164.31 million
Book Value
$1.84 per share

Miscellaneous

Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable
Beta
0.80
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

DRNA Stock Analysis - Frequently Asked Questions

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company earned $62.95 million during the quarter, compared to analysts' expectations of $58.83 million. Dicerna Pharmaceuticals had a negative net margin of 64.53% and a negative trailing twelve-month return on equity of 103.08%. During the same period in the previous year, the company earned ($0.29) EPS.

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals Chief Executive Officer Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among the company's employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

This page (NASDAQ:DRNA) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners